Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30316404 | 1.00 | GPR119 (0.48) | GPR119SMARCA2SMARCA4PBRM1PIK3CA | |
| SCHEMBL29412609 | 1.00 | GPR119 (0.48) | GPR119SMARCA2SMARCA4PBRM1PIK3CA | |
| SCHEMBL24747238 | 1.00 | GPR119 (0.48) | GPR119SMARCA2SMARCA4PBRM1PIK3CA | |
| SCHEMBL30512307 | 0.87 | GPR119 (0.48) | GPR119PIK3CAUSP30ALOX5APFEN1 | |
| SCHEMBL609627 | 0.87 | GPR119 (0.48) | GPR119PIK3CAUSP30ALOX5APFEN1 | |
| SCHEMBL30512308 | 0.85 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1ALOX5AP | |
| SCHEMBL14924376 | 0.85 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1ALOX5AP | |
| SCHEMBL14912289 | 0.85 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1ALOX5AP | |
| SCHEMBL30176849 | 0.85 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1ALOX5AP | |
| SCHEMBL14912467 | 0.85 | SMARCA2 (0.54) | GPR119SMARCA2SMARCA4PBRM1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173008-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-12-24 | — | — | US | disclosed |
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-11-30 | — | — | US | disclosed |
| CN-116568687-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20220332719-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP3A7 | GPR119 2684/4885SMARCA2 3068/4885SMARCA4 3170/4885 |
| US-12173008-B2 | Substituted piperazines as BTK inhibitors | BTK, SYK, ABL1 | GPR119 2806/4885SMARCA2 2593/4885SMARCA4 2733/4885 |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | BTK, SYK, LYN | GPR119 3028/4885SMARCA2 2255/4885SMARCA4 2346/4885 |
| US-20220332719-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | BTK, SYK, LYN | GPR119 3107/4885SMARCA2 3251/4885SMARCA4 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.